Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 15/20 | 0.70 |
| ▸ | F11 | P03951 | 4/20 | 0.48 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672945 | 1.00 | CFD (0.70) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23217472 | 0.89 | CFD (0.56) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL30010103 | 0.89 | CFD (0.56) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23241487 | 0.88 | CFD (0.71) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL21437657 | 0.86 | CFD (0.77) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL21438380 | 0.86 | CFD (0.85) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23217587 | 0.85 | CFD (0.69) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL29672967 | 0.85 | CFD (0.69) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL21437940 | 0.85 | CFD (0.74) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL21438828 | 0.85 | CFD (0.77) | CFDF11TPSB2KLKB1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-09-04 | — | — | US | disclosed |
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275991-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | CFD 1/4885F11 15/4885TPSB2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.